The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

Attention: There is an updated edition available for this report.
   Single User - $2,995
   Site License (one location, 10 users) - $4,750
   Corporate License - $6,000

Published Sep 22, 2013 | 195 Pages | Pub ID: KLI5123810

The World Market for Biosimlars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition

This study, The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment.

Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following:
  • Scientific Differences of Pharmaceuticals and Biopharmaceuticals
  • Market Share of Biosimilar Sales in Comparison to Brand Sales
  • Marketed Biologics with Expired Patents
  • Marketed Biologics with Active Patents
  • Cost Savings From Biosimilar Use
  • World Biosimilar Market Potential by Region 2010-2017
  • World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other)
  • Biosimilars Pipeline by Company and Product Type
For the purposes of this study, Kalorama has focused on the market for products which have lost patent in key markets. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals. Kalorama has identified the biopharmaceuticals that have lost patent protection and are the first products produced by generic companies. As part of its coverage, the following companies were profiled:
  • 3SBio, Inc
  • Actavis, Inc.
  • Apotex, Inc.
  • Beijing Four Rings Biopharmaceutical Co Ltd
  • Biocad
  • Biocon Ltd .
  • Bio Sidus S.A.
  • BioXpress Therapeutics S.A.
  • Boehringer Ingelheim Gmbh
  • Celltrion, Inc.
  • Dong-A Pharmaceutical
  • Dr. Reddy’s Laboratories Limited
  • Epirus Biopharmaceuticals
  • Gedeon Richter
  • Harvest Moon Pharmaceuticals USA,
  • Hospira, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Company
  • Momenta Pharmaceuticals Inc
  • Phage Pharmaceuticals, Inc.
  • Ranbaxy Laboratories Limited
  • Reliance GeneMedix PLC
  • Reliance Life Sciences
  • Samsung Bioepis Co Ltd
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • TEVA Pharmaceutical Industries, Ltd.
  • Wockhardt Ltd.
  • Xiamen Amoytop Biotech Co Ltd.
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times
We were unable to search inside this report.
No results matched your search criteria.

Search for an exact word or phrase by placing the word or phrase in quotation marks ("market trend"). Search for different versions or tenses of a word by placing an asterisk at the end of the word (pharma*).

Please note that your term must be at least three characters long and numbers will be blocked by the # sign.